Skip to content

Price / book at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
10.3×+6.0×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×
TG Therapeutics logo
TG TherapeuticsTGTX
9.1×-17.0×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
IQVIA logo
IQVIAIQV
4.6×-0.6×

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s price / book?
Immunovant, Inc. (IMVT) reported price / book of 5.9× in Q1 2026.
How has Immunovant, Inc.'s price / book changed year-over-year?
Immunovant, Inc.'s price / book increased by 44.5% year-over-year, from 4.1× to 5.9×.
What is the long-term trend for Immunovant, Inc.'s price / book?
Over 5 years (2021 to 2026), Immunovant, Inc.'s price / book has grown at a 8.1% compound annual growth rate (CAGR), from 4× to 5.9×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.